Jade Biosciences to Host Conference Call and Webcast on June 1, 2026, at 8:00 a.m. ET to Discuss Interim Phase 1 Healthy Volunteer Results for JADE101, a Novel, Potentially Best-in-Class Anti-APRIL Monoclonal Antibody in Development for IgA Nephropathy
Jade Biosciences will host a conference call on June 1, 2026, to discuss interim Phase 1 healthy volunteer results for JADE101. JADE101 is a novel anti-APRIL monoclonal antibody in development for IgA nephropathy, a chronic autoimmune kidney disease affecting approximately 169,000 people in the U.S.
Key figures
- Drug Name
- JADE101
- Phase Of Trial
- Phase 1
- Serum half life days
- 27
- Us patient population
- 169000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.